Gene · 10038
Papers2,674
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,674
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PAR-Driven Condensation Maintains Stalled Replication Fork Stability. | bioRxiv | 2026 | 41542599 | PubTator, text mining | PubMed |
| Causal splicing variants revealed by deep-learning integration of single-cell sQTL mapping under influenza infection. | Res Sq | 2026 | 41542048 | PubTator, text mining | PubMed |
| Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib. | CPT Pharmacometrics Syst Pharmacol | 2026 | 41531282 | PubTator, text mining | PubMed |
| PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. | Nucleic Acids Res | 2026 | 41495903 | PubTator, text mining | PubMed |
| Letter to the Editor (Correspondence): Re: Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer. | Lab Invest | 2026 | 41418584 | PubTator, text mining | PubMed |
| Molecular Dynamics and Energetic Insights into Novel PARP15 Inhibitors: A Structural Approach for Targeting BRCA-Mutated Breast Cancer. | Curr Pharm Des | 2026 | 41193446 | PubTator, text mining | PubMed |
| Discovery of selective PARP1/EZH2 inhibitor inducing PANoptosis in triple-negative breast cancer. | Eur J Med Chem | 2026 | 41176893 | PubTator, text mining | PubMed |
| Effects of a cancer-associated mutation and multiple serine phosphorylation on poly(ADP-ribose) polymerase 2. | Biophys J | 2026 | 40734277 | PubTator, text mining | PubMed |
| Targeted therapy for liver cancer: Current status and future directions. | Bioimpacts | 2025 | 41716515 | PubTator, text mining | PubMed |
| The effect of dimeric bisbenzimidazoles on the activity of DNA repair enzymes TDP1, TDP2, PARP1 and PARP2. | Vavilovskii Zhurnal Genet Selektsii | 2025 | 41541557 | PubTator, text mining | PubMed |
| Phylogenomic Reconstruction and Functional Divergence of the PARP Gene Family Illuminate Its Role in Plant Terrestrialization. | Int J Mol Sci | 2025 | 41515998 | PubTator, text mining | PubMed |
| Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis. | NAR Cancer | 2025 | 41480640 | PubTator, text mining | PubMed |
| PARPs and PARP inhibitors: molecular mechanisms and clinical applications. | Mol Biomed | 2025 | 41460301 | PubTator, text mining | PubMed |
| Multi-cohort analysis and experimental study on the function of squalene epoxidase as a ferroptosis inhibitor in HCC. | BMC Cancer | 2025 | 41390395 | PubTator, text mining | PubMed |
| Nucleosome unwrapping and PARP1 allostery drive affinities for chromatin and DNA breaks. | Nat Commun | 2025 | 41360787 | PubTator, text mining | PubMed |
| PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. | Cancer Med | 2025 | 41165261 | PubTator, text mining | PubMed |
| Development of Selective PARP1 Inhibitors for Treatment of Cancer. | ACS Med Chem Lett | 2025 | 41089499 | PubTator, text mining | PubMed |
Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation. | Bioorg Chem | 2025 | 41056654 | PubTator, text mining | PubMed |
| Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. | PLoS One | 2025 | 41004518 | PubTator, text mining | PubMed |
| Translesion DNA polymerases Rev1 and PolH promote LTR-retrotransposon transcription by safeguarding Pol II occupancy in both germline and somatic tissues of Drosophila. | Nucleic Acids Res | 2025 | 40966519 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10038/papers?page=4